Skip to main content
logo
Bicara Therapeutics Inc. (BCAX)
NASDAQ: BCAX · Real-Time Price · USD
26.88
-0.93 (-3.34%)
At close: Jul 28, 2026, 4:00 PM EDT
26.88
0.00 (0.00%)
After-hours: Jul 28, 2026, 4:10 PM EDT

Bicara Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22
Net Income
-157.32-137.95-68-51.99-37.85
Depreciation & Amortization
0.130.110.060.020.01
Stock-Based Compensation
17.4115.017.41.90.81
Other Adjustments
1.031.2-0.0814.06-
Changes in Accounts Payable
19.6710.462.64-8.665.87
Changes in Other Operating Activities
2.24.35-16.77-0.96-0.92
Operating Cash Flow
-116.24-106.83-74.75-45.63-32.08
Operating Cash Flow Growth
-----

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22
Capital Expenditures
--0.28-0.07-0.59-0.19
Sale of Property, Plant & Equipment
--0.06--
Purchases of Investments
--318.17---
Proceeds from Sale of Investments
101----
Investing Cash Flow
101-318.45-0.01-0.59-0.19

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22
Issuance of Common Stock
3.8932.26334.030.150.16
Net Common Stock Issued (Repurchased)
3.8932.26334.030.150.16
Issuance of Preferred Stock
---272.3531.54
Net Preferred Stock Issued (Repurchased)
---272.3531.54
Financing Cash Flow
195.1532.26334.03272.531.7

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22
Net Cash Flow
-138.6-393.03259.27226.28-0.57

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22
Free Cash Flow
-116.24-107.11-74.82-46.21-32.27
Free Cash Flow Growth
-----
Free Cash Flow Per Share
-2.07-1.96-4.45-79.66-75.20
Levered Free Cash Flow
-135.32-123.32-82.14-62.18-33.08
Unlevered Free Cash Flow
-152.28-141.22-96.76-50.08-32.89
SEC Filings: 10-K · 10-Q